How does MDCL's PE Ratio compare to its peers?

MDCL is good value based on its Price-To-Earnings Ratio (21.9x) compared to the peer average (61x).

How does MDCL's PE Ratio compare vs other companies in the European Healthcare Industry?

MDCL is expensive based on its Price-To-Earnings Ratio (21.9x) compared to the European Healthcare industry average (17.1x).

What is MDCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDCL is good value based on its Price-To-Earnings Ratio (21.9x) compared to the estimated Fair Price-To-Earnings Ratio (44.8x).

What is the Fair Price of MDCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MDCL (£5) is trading above our estimate of [[fair value]] (£4.06)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is lower than the current share price.

Mediclinic International (BATS-CHIXE:MDCL) - Stock Price, News & Analysis

MDCL Stock Overview

Mediclinic International plc, together with its subsidiaries, operates private hospitals. More details

MDCL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings are forecast to grow 10.66% per year

Earnings grew by 43.2% over the past year

Risk Analysis

Has a high level of debt

Mediclinic International plc Competitors

Spire Healthcare Group

LSE:SPI

UK£885.2m

CVS Group

AIM:CVSG

UK£596.9m

ConvaTec Group

LSE:CTEC

UK£4.8b

Smith & Nephew

LSE:SN.

UK£8.6b

Price History & Performance

Summary of all time highs, changes and price drops for Mediclinic International
Historical stock prices
Current Share Price	UK£5.00
52 Week High	UK£5.02
52 Week Low	UK£3.89
Beta	0.42
11 Month Change	0.41%
3 Month Change	0.41%
1 Year Change	25.38%
33 Year Change	66.97%
5 Year Change	-14.87%
Change since IPO	-44.06%

Recent updates

Shareholder Returns

	MDCL	GB Healthcare	GB Market
7D	0%	1.4%	1.7%
1Y	25.4%	-22.1%	8.3%

Return vs Industry: MDCL exceeded the UK Healthcare industry which returned 5.1% over the past year.

Return vs Market: MDCL exceeded the UK Market which returned -2.4% over the past year.

Price Volatility

Is MDCL's price volatile compared to industry and market?
MDCL volatility
MDCL Average Weekly Movement	0.5%
Healthcare Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: MDCL has not had significant price volatility in the past 3 months.

Volatility Over Time: MDCL's weekly volatility (0%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1983	33,683	Ronnie van der Merwe	www.mediclinic.com

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers specialist-orientated and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, 2 mental health facilities, and 453 theatres with approximately 11,538 inpatient beds in Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom.

Mediclinic International plc Fundamentals Summary

How do Mediclinic International's earnings and revenue compare to its market cap?
MDCL fundamental statistics
Market cap	UK£3.69b
Earnings (TTM)	UK£169.00m
Revenue (TTM)	UK£3.38b

21.9x

P/E Ratio

1.1x

P/S Ratio

Is MDCL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDCL income statement (TTM)
Revenue	UK£3.38b
Cost of Revenue	UK£2.66b
Gross Profit	UK£728.00m
Other Expenses	UK£559.00m
Earnings	UK£169.00m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.23
Gross Margin	21.52%
Net Profit Margin	5.00%
Debt/Equity Ratio	54.1%

How did MDCL perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

13%

Payout Ratio

MDCL Stock Overview

Rewards

Risk Analysis

Mediclinic International plc Competitors

LSE:SPI

UK£885.2m

AIM:CVSG

UK£596.9m

LSE:CTEC

UK£4.8b

LSE:SN.

UK£8.6b

Price History & Performance

Recent News & Updates

Financial Conduct Authority Cancels the Listing of Mediclinic Shares on the London Stock Exchange and Delisting of Shares from the JSE and the NSX Expects to Take Effect on 7 June 2023

Mediclinic International's Cancellation of Shares from Official List and Main Market of LSE Expected to Take on 30 May 2023; Delisting of Shares from JSE and NSX Expected to Take Effect from Commencement of Trade on 7 June 2023

Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Cancellation of Listing of Mediclinic Shares on the LSE Is Expected on 26 May 2023

Mediclinic International plc (LSE:MDC) acquired Artisan Biomed.

Mediclinic International plc Approves Final Cash Dividend, Payable on 26 August 2022

Recent updates

Financial Conduct Authority Cancels the Listing of Mediclinic Shares on the London Stock Exchange and Delisting of Shares from the JSE and the NSX Expects to Take Effect on 7 June 2023

Mediclinic International's Cancellation of Shares from Official List and Main Market of LSE Expected to Take on 30 May 2023; Delisting of Shares from JSE and NSX Expected to Take Effect from Commencement of Trade on 7 June 2023

Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Cancellation of Listing of Mediclinic Shares on the LSE Is Expected on 26 May 2023

Mediclinic International plc (LSE:MDC) acquired Artisan Biomed.

Mediclinic International plc Approves Final Cash Dividend, Payable on 26 August 2022

Mediclinic International plc to Delist

Mediclinic International plc Approves Final Cash Dividend

Upcoming dividend of UK£0.03 per share

Remgro Wants Equal Partner in Possible Mediclinic Buyout

Mediclinic International Ordinary Shares to Be Deleted from OTC Equity

Independent Non-Executive Director recently bought UK£73k worth of stock

Full year 2022 earnings released: EPS: UK£0.20 (vs UK£0.092 in FY 2021)

Mediclinic International plc to Report First Half, 2023 Results on Nov 16, 2022

High number of new directors

Mediclinic International plc to Report Fiscal Year 2022 Results on May 25, 2022

High number of new directors

High number of new directors

First half 2022 earnings released: EPS UK£0.088 (vs UK£0.02 in 1H 2021)

High number of new directors

High number of new directors

Senior Independent Director J. Grieve has left the company

Independent Non-Executive Director Trevor Petersen has left the company

Full year 2021 earnings released: EPS UK£0.092 (vs UK£0.43 loss in FY 2020)

Full year 2021 earnings released: EPS UK£0.092 (vs UK£0.43 loss in FY 2020)

Mediclinic International plc Provides Revenue Guidance for Fiscal 2022

New 90-day high: UK£3.06

Non-Executive Director recently sold UK£52k worth of stock

Shareholder Returns

Price Volatility

About the Company

Mediclinic International plc Fundamentals Summary

21.9x

1.1x

Earnings & Revenue

Dividends

0.6%

13%